-
BeiGene Chairman Lei Qiang Ou: After 2024, it is expected that 10 new molecules will enter the clinical JPM conference every year
Time of Update: 2023-02-01
Anti-PD-1 monoclonal antibody tislelizumab ▲BeiGene's internal R&D pipeline (Image source: Screenshot of BeiGene's speech report)▲BeiGene's internal R&D pipeline (Image source: BeiGene speech report screenshot) ▲▲Bcl-2 inhibitor BGB-11417: In the second half of 2023, a global pivotal trial in combination with zebratinib for the first-line treatment of CLL will be initiated, and data from ongoing clinical studies is expected to be available.
-
Small molecule antagonists for migraine-prevention CGRP subjects are expected to be approved next year
Time of Update: 2020-11-07
Nurtec ODT, the first CGRP-subject antagonist with a rapidly dissolving agent, has been approved by the FDA for acute treatment of migraines in adults.
-
30 years from now, small molecule drugs and antibody drugs will no longer be mainstream?
Time of Update: 2020-08-01
"We have a lot of room to improve the specificity and effectiveness of AAV vectors by transforming the AAV shell protein," said Dr. Federico Mingozzi, chief scientific officer of Spark Therapeutics, another guest on the "Next Generation Medicine: Cell Therapy, Gene Therapy and other" online forum.
-
The development trend of anti-tumor drugs in the future! Which small molecule kinase inhibitors have been approved by the FDA in the past 20 years?
Time of Update: 2020-07-19
Guide: Only the innovation of science and technology and multidisciplinary joint innovation efforts, in order to faster small molecules to the market! caption: the treatment of cancer, whether in te
-
The development trend of anti-tumor drugs in the future! Which small molecule kinase inhibitors have been approved by the FDA in the past 20 years?
Time of Update: 2020-07-18
inscription: Cancer treatment, whether in terms of the economic properties of the drug or the affordability of patients, small molecule-targeted drugs have become and will be an important clinical
-
30 years from now, small molecule drugs and antibody drugs will no longer be mainstream?
Time of Update: 2020-07-09
The Bio International Convention is one of the largest annual events in the biotechnology and pharmaceutical industries Affected by the new crown outbreak, local time on June 8, BIO 2020 conference op
-
Small molecule new drug patent applied by Hengrui in recent years
Time of Update: 2020-04-03
Wo2007079666 paclitaxel derivative, for the treatment of tumor Wo2007085188 VEGFR / PDGFR inhibitors, sunitinib analogues, for cancer treatment Wo2008089636 DPP-4 inhibitor, wiggliptin analogue, in th